News | November 01, 2022
Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
His experience covers a wide range of areas including advisory services in the field of accounting, taxation, corporate and commercial laws, and regulatory matters
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Subscribe To Our Newsletter & Stay Updated
